Bringing the Investor Perspective to Japan’s Growth Strategy: Incubate Coalition Japan in Tokyo

June 7–10, 2026 | Tokyo, Japan

Incubate Coalition Japan (ICJ) returned to Tokyo in June 2026 with a delegation of U.S. venture investors at an important moment for Japan’s life sciences policy. The visit coincided with the final drafting of the Takaichi administration’s Honebuto and Growth Strategy, both of which identify pharmaceuticals as a strategic sector for Japan’s economic growth.

Over the course of the visit, the delegation met with members of the National Diet, officials from the Ministry of Health, Labour and Welfare (MHLW) and Ministry of Economy, Trade and Industry (METI), venture investors, media, and leaders from other stakeholders across the biotech ecosystem in Tokyo.

Bringing the Investor Perspective Directly to Policymakers

In conversations with Diet members and officials from MHLW and METI, the delegation discussed the connection between Japan’s drug pricing policies, private investment, biotechnology company formation, and the government’s broader economic growth objectives.

A recurring theme was how life sciences is increasingly seen as a strategic growth industry capable of creating high-value jobs, attracting international capital, generating economic activity, and strengthening Japan’s global competitiveness. The delegation emphasized that frequent price revisions and limited predictability can make long-term investment more difficult and contribute to medicines and biotechnology companies being developed or launched elsewhere.

Connecting Drug Pricing Reform to Japan’s Growth Ambitions

Discussions with MHLW and METI reinforced the government’s growing focus on biotechnology and drug discovery as strategic industries.

Ministry officials highlighted national efforts to support R&D, build the biotechnology ecosystem, develop talent, and expand access to capital. They also discussed the challenges created when companies determine that investment can be more effectively recouped by developing products outside Japan and expressed interest in incorporating more international investor perspectives into the government’s work on startups and talent development.

Ministry officials similarly framed life sciences as a strategic industrial sector alongside other national priorities and discussed efforts to expand domestic capabilities across the industry. The conversation highlighted an opportunity for ICJ to contribute data and investor expertise as Japan develops policies intended to translate scientific strength into economic growth.

Building Public Understanding of the Value of Innovation

Another theme that emerged repeatedly throughout the trip was how successful policy reform will require a broader public understanding of how medicines are developed and financed.

Government stakeholders noted that the cost and risk involved in developing innovative medicines, and the fact that many potential therapies never successfully reach patients, are not always well understood. Participants discussed the need to better communicate how pharmaceutical innovation affects patient access, economic growth, and the sustainability of the broader biotechnology ecosystem.

Strengthening Japan’s Startup and Investment Ecosystem

The delegation also met with leaders across Japan’s biotechnology ecosystem to discuss the practical challenges facing startups and investors.

These conversations underscored that drug pricing reform is one part of a larger challenge. Building a globally competitive biotechnology ecosystem requires stronger commercialization pathways, experienced talent, startup infrastructure, and connections between researchers, entrepreneurs, investors, and established companies.

Deepening ICJ’s Presence in Japan

The visit concluded with a dinner bringing together members and prospective members of the Incubate Coalition Japan Advisory Council. The group discussed how ICJ can maintain a more consistent presence in Japan between delegation visits, expand its public advocacy and media engagement, and connect U.S. investors more closely with Japanese startups and ecosystem leaders.

The conversations throughout the week made clear that there is significant demand for the perspective ICJ brings. Policymakers and ecosystem leaders repeatedly emphasized that the voice of international investors remains underrepresented in Japanese life sciences policy discussions and encouraged continued engagement.

Continuing the Momentum

The June visit came at a pivotal point in Japan’s efforts to make life sciences a larger part of its national growth strategy. ICJ will continue working with policymakers and ecosystem partners to provide investor perspectives, develop stronger evidence around the economic and patient impact of life sciences innovation, expand public understanding of the value of medicines, and strengthen connections between the U.S. and Japanese biotechnology communities.

Japan has the science, talent, and ambition to become an even more important global center for biotechnology. Creating a policy environment that rewards innovation and gives investors confidence to commit capital for the long term will be essential to turning that potential into new companies, economic growth, and medicines for patients.